| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1996;94:3334-3340.)
© 1996 American Heart Association, Inc.
Articles |
A Novel Site-Targeted Ultrasonic Contrast Agent With Broad Biomedical Application
the Department of Medicine, Division of Cardiology, Barnes-Jewish Hospital of St Louis (G.M.L., M.J.S., D.H.C., A.M.S., S.A.W.), and the Department of Physics (K.D.W., J.G.M., S.A.W.), Washington University, St Louis, Mo; HemaGen/PFC Inc (W.P.C.), St Louis, Mo; the Department of Medicine, Division of Cardiology, Washington University School of Medicine (D.R.A.), St Louis, Mo; and the Division of Hematology, National Institute for Biological Standards and Control (P.J.G.), Hertfordshire, UK.
Correspondence to Samuel A. Wickline, MD, Department of Medicine, Division of Cardiology, Barnes-Jewish Hospital, Washington University Medical Center, St Louis, MO 63130. E-mail SAW@howdy.wustl.edu.
Background In this work, we report a novel targetable ultrasonic contrast agent with the potential to noninvasively define and localize myriad pathological tissues for diagnosis or therapy. The agent is a biotinylated, lipid-coated, perfluorocarbon emulsion that has low inherent echogenicity unless bound to a surface or itself.
Methods and Results In study 1, emulsions with and without biotin were suspended in buffered saline and imaged with a 7.5-MHz linear-array transducer. Neither emulsion manifested significant ultrasonic backscatter until avidin was added. Avidin-induced aggregation produced a marked enhancement in backscatter from the biotinylated but not from the control emulsion. In study 2, porcine fibrin clots in vitro were pretargeted with biotinylated antifibrin monoclonal antibodies and then exposed to avidin and then to biotinylated or control perfluorocarbon emulsions. The basal acoustic reflectivity of clots imaged with a 7.5-MHz linear-array transducer was uniformly low and was increased substantially by exposure to the targeted biotinylated emulsion. In study 3, partially occlusive arterial thrombi were created in dogs and then exposed to antifibrin antibodies and avidin in situ. Biotinylated or control emulsion was administered either in situ or systemically. At baseline, all thrombi were undetectable with a 7.5-MHz linear-array transducer. Thrombi exposed to antifibrin-targeted contrast exhibited increased echogenicity (P<.05); control thrombi remained acoustically undetectable.
Conclusions These data provide the first in vivo demonstration of a site-specific ultrasonic contrast agent and have potential for improved sensitivity and specificity for noninvasive diagnosis of thrombi and other pathological diseases.
Key Words: ultrasonics • contrast media • fibrin • thrombus • avidin
This article has been cited by other articles:
 |
|
 |
|
  F. G. Blankenberg In Vivo Detection of Apoptosis J. Nucl. Med., June 1, 2008; 49(Suppl_2): 81S - 95S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Cyrus, H. Zhang, J. S. Allen, T. A. Williams, G. Hu, S. D. Caruthers, S. A. Wickline, and G. M. Lanza Intramural Delivery of Rapamycin With {alpha}v{beta}3-Targeted Paramagnetic Nanoparticles Inhibits Stenosis After Balloon Injury Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 820 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Honda and P. J. Fitzgerald Frontiers in Intravascular Imaging Technologies Circulation, April 15, 2008; 117(15): 2024 - 2037. [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Willmann, R. Paulmurugan, K. Chen, O. Gheysens, M. Rodriguez-Porcel, A. M. Lutz, I. Y. Chen, X. Chen, and S. S. Gambhir US Imaging of Tumor Angiogenesis with Microbubbles Targeted to Vascular Endothelial Growth Factor Receptor Type 2 in Mice Radiology, February 1, 2008; 246(2): 508 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Palmowski, J. Huppert, G. Ladewig, P. Hauff, M. Reinhardt, M. M. Mueller, E. C. Woenne, J. W. Jenne, M. Maurer, G. W. Kauffmann, et al. Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects Mol. Cancer Ther., January 1, 2008; 7(1): 101 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Partlow, J. Chen, J. A. Brant, A. M. Neubauer, T. E. Meyerrose, M. H. Creer, J. A. Nolta, S. D. Caruthers, G. M. Lanza, and S. A. Wickline 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons FASEB J, June 1, 2007; 21(8): 1647 - 1654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Alonso, A. Della Martina, M. Stroick, M. Fatar, M. Griebe, S. Pochon, M. Schneider, M. Hennerici, E. Allemann, and S. Meairs Molecular Imaging of Human Thrombus With Novel Abciximab Immunobubbles and Ultrasound Stroke, May 1, 2007; 38(5): 1508 - 1514. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Hauff, M. Reinhardt, A. Briel, N. Debus, and M. Schirner Molecular Targeting of Lymph Nodes with L-Selectin Ligand-specific US Contrast Agent: A Feasibility Study in Mice and Dogs Radiology, June 1, 2004; 231(3): 667 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Jaffer and R. Weissleder Seeing Within: Molecular Imaging of the Cardiovascular System Circ. Res., March 5, 2004; 94(4): 433 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Hamilton, S.-L. Huang, D. Warnick, M. Rabbat, B. Kane, A. Nagaraj, M. Klegerman, and D. D. McPherson Intravascular ultrasound molecular imaging of atheroma components in vivo J. Am. Coll. Cardiol., February 4, 2004; 43(3): 453 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H-D Liang and M J K Blomley The role of ultrasound in molecular imaging Br. J. Radiol., December 1, 2003; 76(suppl_2): S140 - S150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Winter, A. M. Morawski, S. D. Caruthers, R. W. Fuhrhop, H. Zhang, T. A. Williams, J. S. Allen, E. K. Lacy, J. D. Robertson, G. M. Lanza, et al. Molecular Imaging of Angiogenesis in Early-Stage Atherosclerosis With {alpha}v{beta}3-Integrin-Targeted Nanoparticles Circulation, November 4, 2003; 108(18): 2270 - 2274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Du, Y. Yang, C. Le Visage, H. H. Chen, R. DeJong, B. Qiu, D. Wang, K. W. Leong, U. M. Hamper, and X. Yang In Vivo US Monitoring of Catheter-based Vascular Delivery of Gene Microspheres in Pigs: Feasibility Radiology, August 1, 2003; 228(2): 555 - 559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Yang Imaging of Vascular Gene Therapy Radiology, July 1, 2003; 228(1): 36 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Lanza, X. Yu, P. M. Winter, D. R. Abendschein, K. K. Karukstis, M. J. Scott, L. K. Chinen, R. W. Fuhrhop, D. E. Scherrer, and S. A. Wickline Targeted Antiproliferative Drug Delivery to Vascular Smooth Muscle Cells With a Magnetic Resonance Imaging Nanoparticle Contrast Agent: Implications for Rational Therapy of Restenosis Circulation, November 26, 2002; 106(22): 2842 - 2847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Jaffer, C.-H. Tung, R. E. Gerszten, and R. Weissleder In Vivo Imaging of Thrombin Activity in Experimental Thrombi With Thrombin-Sensitive Near-Infrared Molecular Probe Arterioscler. Thromb. Vasc. Biol., November 1, 2002; 22(11): 1929 - 1935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hamilton, S.-L. Huang, D. Warnick, A. Stein, M. Rabbat, T. Madhav, B. Kane, A. Nagaraj, M. Klegerman, R. MacDonald, et al. Left Ventricular Thrombus Enhancement After Intravenous Injection of Echogenic Immunoliposomes: Studies in a New Experimental Model Circulation, June 11, 2002; 105(23): 2772 - 2778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. A. Fayad and V. Fuster Clinical Imaging of the High-Risk or Vulnerable Atherosclerotic Plaque Circ. Res., August 17, 2001; 89(4): 305 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Demos, H. Alkan-Onyuksel, B. J. Kane, K. Ramani, A. Nagaraj, R. Greene, M. Klegerman, and D. D. McPherson In vivo targeting of acoustically reflective liposomes for intravascular and transvascular ultrasonic enhancement J. Am. Coll. Cardiol., March 1, 1999; 33(3): 867 - 875. [Abstract] [Full Text] [PDF]
|
|